bi-4SCAR CD19/70 / SZGIMI - LARVOL DELTA

CD19/70 Bi-specific CAR-T Cell Therapy (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Jun 2026 ➔ Dec 2030 | Trial primary completion date: Dec 2025 ➔ Dec 2029

Trial completion date • Trial primary completion date • Oncology • CD19

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma (ASH 2023) - "All patients received cyclophosphamide/fludarabine chemotherapy conditioning 1-2 days before infusions of CAR-T cells. In summary, our research data confirms that the efficacy and safety of CD19/CD70 dual targeted CAR-T cells infusion, continued follow-up will determine whether the CD19/CD70 CAR-T cells therapy can obtain long term overall survival in our study. How to further improve the efficacy and safety of dual target CAR-T is still worth exploring. It's needed to optimize multi-specific targeting by CAR-T cells to improve the efficacy both in B cell malignancies and other hematological malignancies."

CAR T-Cell Therapy • Clinical • IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gene Therapies • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CASP9 • CD27 • CD70

CD19/70 Bi-specific CAR-T Cell Therapy (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute

CAR T-Cell Therapy • New P1/2 trial • Oncology • CD19